Edgewise Therapeutics, Inc. (EWTX)
40.45
+0.92
(+2.33%)
USD |
NASDAQ |
Oct 28, 16:00
40.45
0.00 (0.00%)
After-Hours: 20:00
Edgewise Therapeutics Enterprise Value : 3.803B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 3.803B |
| October 26, 2026 | 3.764B |
| October 23, 2026 | 3.780B |
| October 22, 2026 | 3.853B |
| October 21, 2026 | 3.816B |
| October 20, 2026 | 3.827B |
| October 19, 2026 | 3.630B |
| October 16, 2026 | 3.551B |
| October 15, 2026 | 3.660B |
| October 14, 2026 | 3.533B |
| October 13, 2026 | 3.453B |
| October 12, 2026 | 3.687B |
| October 09, 2026 | 3.753B |
| October 08, 2026 | 3.771B |
| October 07, 2026 | 3.808B |
| October 06, 2026 | 3.856B |
| October 05, 2026 | 3.886B |
| October 02, 2026 | 4.005B |
| October 01, 2026 | 3.906B |
| September 30, 2026 | 3.919B |
| September 29, 2026 | 3.767B |
| September 28, 2026 | 3.831B |
| September 25, 2026 | 3.783B |
| September 24, 2026 | 3.979B |
| September 23, 2026 | 3.967B |
| Date | Value |
|---|---|
| September 22, 2026 | 4.340B |
| September 21, 2026 | 4.354B |
| September 18, 2026 | 4.427B |
| September 17, 2026 | 4.602B |
| September 16, 2026 | 4.440B |
| September 15, 2026 | 4.245B |
| September 14, 2026 | 4.352B |
| September 11, 2026 | 4.328B |
| September 10, 2026 | 4.166B |
| September 09, 2026 | 4.219B |
| September 08, 2026 | 4.266B |
| September 04, 2026 | 4.185B |
| September 03, 2026 | 4.064B |
| September 02, 2026 | 4.067B |
| September 01, 2026 | 4.096B |
| August 31, 2026 | 4.045B |
| August 28, 2026 | 4.151B |
| August 27, 2026 | 4.306B |
| August 26, 2026 | 4.326B |
| August 25, 2026 | 4.308B |
| August 24, 2026 | 4.363B |
| August 21, 2026 | 4.304B |
| August 20, 2026 | 4.209B |
| August 19, 2026 | 4.548B |
| August 18, 2026 | 4.297B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.62M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -73.22M |
| Fulcrum Therapeutics, Inc. | -31.31M |
| Definium Therapeutics, Inc. | 3.935B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.33M |
| Total Expenses (Quarterly) | 57.33M |
| EPS Diluted (Quarterly) | -0.5324 |
| Earnings Yield | -4.57% |
| Normalized Earnings Yield | -4.572 |